Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 11/07/2025 BST			After hours 21:19:21
109.64 ^USD	-4.28%		109.95	+0.28%

06:39pm	Equity Markets Mostly Fall Intraday as Traders Track Tariff Updates	MT
03:04pm	HSBC Adjusts Price Target on Gilead Sciences to $91 From $93, Maintains Hold Rating	MT

Projected Income Statement: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	24,689	27,305	27,281	27,116	28,754	28,697	29,862	31,332
Change	-	10.6%	-0.09%	-0.6%	6.04%	-0.2%	4.06%	4.92%
EBITDA ¹	13,184	14,598	14,283	13,177	11,287	15,692	16,241	17,361
Change	-	10.73%	-2.16%	-7.74%	-14.34%	39.02%	3.5%	6.9%
EBIT ¹	11,704	12,548	12,180	10,484	8,520	13,027	13,758	14,592
Change	-	7.21%	-2.93%	-13.92%	-18.73%	52.9%	5.61%	6.07%
Interest Paid ¹	-984	-1,001	-935	-944	-977	-952.9	-880.9	-863.8
Earnings before Tax (EBT) ¹	1,669	8,278	5,814	6,859	690	9,181	10,370	11,038
Change	-	395.99%	-29.77%	17.97%	-89.94%	1,230.57%	12.95%	6.44%
Net income ¹	123	6,225	4,592	5,665	480	6,761	6,939	9,279
Change	-	4,960.98%	-26.23%	23.37%	-91.53%	1,308.49%	2.64%	33.72%
Announcement Date	04/02/21	01/02/22	02/02/23	06/02/24	11/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	5,143	6,577	7,421	6,423	6,217	7,421	7,244	6,590	6,260	7,042	7,389	6,352	6,599	7,051	7,115	6,686	6,954	7,545	7,569	6,667	6,972	7,409	7,565	6,890	7,253	7,648	8,026
Change	-	27.88%	12.83%	-13.45%	-3.21%	19.37%	-2.39%	-9.03%	-5.01%	12.49%	4.93%	-14.03%	3.89%	6.85%	0.91%	-6.03%	4.01%	8.5%	0.32%	-11.92%	4.57%	6.28%	2.09%	-8.92%	5.27%	5.45%	4.95%
EBITDA ¹	2,344	3,807	3,919	3,959	3,695	4,902	2,042	4,049	3,195	3,811	3,227	2,883	3,258	3,908	3,427	-427	3,959	3,948	3,807	3,589	4,019	4,184	4,142	3,868	4,069	4,403	4,413
Change	-	62.41%	2.94%	1.02%	-6.67%	32.67%	-58.34%	98.29%	-21.09%	19.28%	-15.32%	-10.66%	13.01%	19.95%	-12.31%	-112.46%	1,027.17%	-0.28%	-3.57%	-5.73%	11.98%	4.11%	-1%	-6.62%	5.2%	8.21%	0.23%
EBIT ¹	1,995	3,452	3,492	3,486	3,176	4,379	1,507	3,524	2,670	3,286	2,699	2,243	2,277	3,224	2,739	-1,117	3,265	3,258	3,114	2,893	3,223	3,539	3,366	3,090	3,328	3,637	3,851
Change	-	73.03%	1.16%	-0.17%	-8.89%	37.88%	-65.59%	133.84%	-24.23%	23.07%	-17.86%	-16.9%	1.52%	41.59%	-15.04%	-140.78%	392.3%	-0.21%	-4.42%	-7.1%	11.4%	9.8%	-4.89%	-8.18%	7.69%	9.3%	5.86%
Charge d'intérêts ¹	-240	-236	-267	-257	-256	-250	-238	-238	-242	-229	-227	-230	-230	-232	-252	-254	-237	-238	-248	-260	-234.3	-238.8	-230.9	-238.8	-228.4	-227.8	-220.4
Earnings before Tax (EBT) ¹	-2,973	825	1,814	2,264	1,817	3,438	759	-152	1,503	2,432	2,031	1,300	1,588	2,318	1,653	-4,486	2,053	956	2,168	1,649	2,334	2,713	2,503	2,507	2,701	3,139	2,823
Change	-	127.75%	119.88%	24.81%	-19.74%	89.21%	-77.92%	-120.03%	1,088.82%	61.81%	-16.49%	-35.99%	22.15%	45.97%	-28.69%	-371.39%	145.76%	-53.43%	126.78%	-23.94%	41.51%	16.25%	-7.73%	0.16%	7.74%	16.22%	-10.07%
Net income ¹	-3,339	360	1,551	1,729	1,522	2,592	382	19	1,144	1,789	1,640	1,010	1,045	2,180	1,429	-4,170	1,614	1,253	1,783	1,315	1,886	2,142	2,059	1,967	2,130	2,428	2,302
Change	-	110.78%	330.83%	11.48%	-11.97%	70.3%	-85.26%	-95.03%	5,921.05%	56.38%	-8.33%	-38.41%	3.47%	108.61%	-34.45%	-391.81%	138.71%	-22.37%	42.3%	-26.25%	43.4%	13.6%	-3.87%	-4.49%	8.29%	13.97%	-5.15%
Announcement Date	30/07/20	28/10/20	04/02/21	29/04/21	29/07/21	28/10/21	01/02/22	28/04/22	02/08/22	27/10/22	02/02/23	27/04/23	03/08/23	07/11/23	06/02/24	25/04/24	08/08/24	06/11/24	11/02/25	24/04/25	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	30,879	27,449	18,845	17,723	16,720	11,522	6,274	678
Change	-	-11.11%	-31.35%	-5.95%	-5.66%	-31.09%	-45.55%	-89.19%
Announcement Date	04/02/21	01/02/22	02/02/23	06/02/24	11/02/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	650	579	728	585	523	562	575.2	608.7
Change	-	-10.92%	25.73%	-19.64%	-10.6%	7.45%	2.35%	5.82%
Free Cash Flow (FCF) ¹	7,518	10,805	8,344	7,421	10,305	11,090	11,947	12,317
Change	-	43.72%	-22.78%	-11.06%	38.86%	7.62%	7.72%	3.1%
Announcement Date	04/02/21	01/02/22	02/02/23	06/02/24	11/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	53.4%	53.46%	52.36%	48.59%	39.25%	54.68%	54.39%	55.41%
EBIT Margin (%)	47.41%	45.95%	44.65%	38.66%	29.63%	45.39%	46.07%	46.57%
EBT Margin (%)	6.76%	30.32%	21.31%	25.3%	2.4%	31.99%	34.73%	35.23%
Net margin (%)	0.5%	22.8%	16.83%	20.89%	1.67%	23.56%	23.24%	29.62%
FCF margin (%)	30.45%	39.57%	30.59%	27.37%	35.84%	38.65%	40.01%	39.31%
FCF / Net Income (%)	6,112.2%	173.57%	181.71%	131%	2,146.88%	164.03%	172.16%	132.74%
Profitability
ROA	0.19%	9.13%	13.97%	13.49%	9.57%	13.51%	14.81%	14.5%
ROE	43.84%	46.79%	43.33%	38.46%	27.6%	43.18%	38.5%	34.95%
Financial Health
Leverage (Debt/EBITDA)	2.34x	1.88x	1.32x	1.34x	1.48x	0.73x	0.39x	0.04x
Debt / Free cash flow	4.11x	2.54x	2.26x	2.39x	1.62x	1.04x	0.53x	0.06x
Capital Intensity
CAPEX / Current Assets (%)	2.63%	2.12%	2.67%	2.16%	1.82%	1.96%	1.93%	1.94%
CAPEX / EBITDA (%)	4.93%	3.97%	5.1%	4.44%	4.63%	3.58%	3.54%	3.51%
CAPEX / FCF (%)	8.65%	5.36%	8.72%	7.88%	5.08%	5.07%	4.81%	4.94%
Items per share
Cash flow per share ¹	6.467	9.021	7.189	6.364	8.628	9.258	10.36	10.82
Change	-	39.48%	-20.31%	-11.47%	35.57%	7.3%	11.87%	4.52%
Dividend per Share ¹	2.72	2.84	2.92	3	3.08	3.246	3.396	3.523
Change	-	4.41%	2.82%	2.74%	2.67%	5.39%	4.62%	3.75%
Book Value Per Share ¹	14.43	16.8	17.01	18.08	15.45	17.99	21.45	25.22
Change	-	16.41%	1.25%	6.32%	-14.58%	16.47%	19.24%	17.56%
EPS ¹	0.1	4.93	3.64	4.5	0.38	5.443	5.612	7.522
Change	-	4,830%	-26.17%	23.63%	-91.56%	1,332.46%	3.1%	34.03%
Nbr of stocks (in thousands)	1,253,528	1,254,384	1,254,244	1,246,042	1,246,266	1,243,929	1,243,929	1,243,929
Announcement Date	04/02/21	01/02/22	02/02/23	06/02/24	11/02/25	-	-	-